Takeda Oncology (Millennium Pharmaceuticals, Inc) is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, developing therapies for the treatment of cancer.
In May 2008, Millennium was acquired by Takeda Pharmaceutical for $8.8 billion USD and is operating as an independent wholly owned subsidiary of Takeda.
- In Dec 2020, the US FDA approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, Relugolix, (ORGOVYX, Myovant Sciences, Inc.) for adult patients with advanced prostate cancer.
- Earlier in 2016, Myovant Sciences Ltd. was launched through a strategic partnership between Roivant Sciences and Takeda, with Takeda granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries) to relugolix (TAK-385).
- In May 2020, the US FDA approved brigatinib (ALUNBRIG®) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Brigatinib is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity.
- In July 2020, U.S. FDA granted Breakthrough Therapy Designation to Pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS).
- In Apr 2020, U.S. FDA granted Breakthrough Therapy Designation to Mobocertinib (TAK-788) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
- In Nov 2015, US FDA approved Ixazomib (Ninlaro) for the treatment of multiple myeloma, in combination with other drugs.
- In 2011, Brentuximab vedotin/Adcetris™, was approved by FDA for Anaplastic Large Cell Lymphoma and hodgkin’s lymphoma.
- In 2009, Mepact® was approved in Europe for osteosarcoma. It was denied approval by US FDA in 2007 due to lack of clinical data.
- In May 2003, Bortezomib/Velcade® was approved by FDA for multiple myeloma and in Dec 2006 for mantle cell lymphoma, who have received at least one prior therapy.
- Bortezomib/Velcade® was developed by Millennium in collaboration with Johnson & Johnson Pharmaceutical.